First FDA approval for CAR-T cell therapy

The FDA formally approved the first CAR-T cell therapy for leukaemia. The treatment, which goes by the brand name Kymriah, is produced by Novartis. It will treat acute lymphocytic leukaemia (ALL), a common type of childhood cancer. Current treatments achieve remission rates of 85%. Kymriah is a new therapy for those patients who do not respond to standard treatments or who have relapsed. CAR-T cell therapies for other types of leukaemia are being developed and the treatment is currently also being explored for sold tumours.


Registration for the 25th Anniversary Congress is now open

Congress Rates

Academic member €650
Academic non-member €880
Industry member €980
Industry non-member €1290
Student member €310

*Student registrations include complimentary ESGCT Membership

Becoming an ESGCT Academic or Industry member can save you up to 30% on Non-member congress rates

Please see here for full rates including Workshops